CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
COSCIENS Biopharma Inc.
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026
$6.49+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $20.66M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$3.87 (+147.7%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
COSCIENS Biopharma Inc. saw revenue fall 21.8% to $7.50M over the twelve months to Dec 31, 2025. Free cash flow was -$9.18M.
Revenue
$7.50M
-21.8% vs. a year earlier
Operating income
-$10.68M
TTM Q4 2025
Free cash flow
-$9.18M
TTM Q4 2025
EPS, diluted
-$3.27
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2025
Valuation
- Market cap
- $20.66M
- P/E ratio
- –
- Price to sales
- 2.76
- Price to book
- 5.38
- Dividend yield
- –
- Free cash flow yield
- -44.43%
Fundamentals
- Revenue
- $7.50M
- EPS, diluted
- -$3.27
- Free cash flow
- -$9.18M
- Book value per share
- $1.21
- Diluted shares
- 3M
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$7.50M-21.8% YoY
Gross profit
$2.65M-44.0% YoY
Operating income
-$10.68M
EPS, diluted
-$3.27
Free cash flow
-$9.18M
Reported period